Dr. Kaimakliotis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1701 N Senate Ave
Indianapolis, IN 46202Phone+1 317-948-6351Fax+1 317-944-0174
Education & Training
Yale-New Haven Medical CenterResidency, Urology, 2008 - 2012
Yale School of MedicineClass of 2007
Certifications & Licensure
IN State Medical License 2013 - 2025
CT State Medical License 2012 - 2013- American Board of Urology Urology
Clinical Trials
- A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer Start of enrollment: 2022 Mar 01
Roles: Contact
Publications & Presentations
PubMed
- 30 citationsPatients With Muscle Invasive Bladder Cancer with Non-luminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy.Yair Lotan, Joep J. de Jong, Vinnie Y. T. Liu, Tarek A. Bismar, Stephen A. Boorjian
The Journal of Urology. 2021-10-13 - 28 citationsPlasmacytoid/diffuse urothelial carcinoma: a single-institution immunohistochemical and molecular study of 69 patients.Carmen M. Perrino, John N. Eble, Chia Sui Kao, Rumeal D Whaley, Liang Cheng
Human Pathology. 2019-05-03 - 53 citationsPlasmacytoid bladder cancer: variant histology with aggressive behavior and a new mode of invasion along fascial planes.Hristos Z. Kaimakliotis, M. Francesca Monn, Liang Cheng, Timothy A. Masterson, K. Clint Cary
Urology. 2014-05-01
Authored Content
- Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future PerspectivesSeptember 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
